

About

OncoHost's PROphet® test allows you and your physician to understand the dynamic interplay between you, your tumor, and your treatment.

The PROphet® report will provide your physician with viable treatment options tailored specifically to you, making your cancer therapy highly personalized.

Thank you for including OncoHost in your journey.

Next Steps:

- 1 Per your physician's request, a blood draw will be performed in clinic, or a phlebotomist will reach out to you to schedule an appointment for a blood draw at your preferred location.
- 2 The phlebotomist will draw one tube of blood for testing. No additional blood tests are required for our analysis.
- 3 Your blood sample will be sent via overnight shipping to our lab for processing and analysis. No additional steps are required by you at this time.
- 4 Once testing is complete, your physician will receive your personalized PROphet® report and will be in touch with you to discuss the results.

OncoHost FAQs

1. What is PROphet®?

- ✓ PROphet® is a first-of-its-kind proteomic pattern analysis tool that assesses clinical benefit to treatment, enabling physicians to provide truly personalized care.
- ✓ The PROphet® test is a laboratory developed test (LDT) performed at OncoHost's CLIA-certified and CAP-accredited laboratory located in North Carolina.
- ✓ Analyzing just one pre-treatment blood sample, PROphet® identifies proteomic patterns unique to you that serve as indicators of your resistance mechanisms. These patterns can help predict your likeliness to obtain clinical benefit from PD-1/PD-L1 inhibitor immunotherapy-based treatment.
- ✓ Utilizing bioinformatics and artificial intelligence, PROphet® produces a personalized report answering an important clinical question:

What is the optimal first line of therapy for you?



Pre-treatment blood test collected at patient's own home or in-clinic



High-throughput proteomic assay



Bioinformatics and AI



The PROphet® report with analysis of clinical benefit and actionable clinical insights is sent to your physician.

The blood sample is analyzed and processed at OncoHost's CLIA-registered and CAP-accredited* in Cary, North Carolina

*In effect until June 30, 2026.

**OncoHost's Patient Financial Assistance Program is only available to patients whose tests were ordered within the United States and U.S. territories.

2. What is proteomic profiling? Why do we use this type of test?

Proteomics is the large-scale analysis of proteins and their levels, a powerful tool in the fight against cancer. Your blood contains thousands of proteins in various levels. These proteins are derived from different cells in the body, including tumor and immune cells, and, as such, can serve as a depiction of your health condition.

PROphet[®] employs SomaScan technology that scans approximately 7,000 proteins in your plasma, including cytokines, chemokines, growth factors and enzymes. These are all associated with therapy resistance and tumor spread.

The result of this proteomic analysis provides your physician with precise, personalized clinical insights, allowing them to administer a treatment plan tailored to you.



Enable early prediction of individual clinical benefit from PD-1/PD-L1 immunotherapy.

3. How does proteomic testing differ from next-generation sequencing (NGS)?

Proteomic profiling focuses on the proteins in your blood, identifying biomarkers that can indicate the occurrence of biological processes taking place in the tumor and within the body that potentially affect the success of treatment.

Next-generation sequencing (NGS) is performed to obtain important information regarding the genomic and genetic make-up of your tumor. Some genetic alterations are known as “driver mutations” or “biomarkers,” which provide vital data to help guide your overall treatment plan.

Proteomic analysis used alongside NGS testing can offer your physician valuable insights into your tumor growth, the characteristics of your tumor, and how you will likely respond to treatment.


4. What will my physician learn from the PROphet[®] report?

Your personalized report will show either a POSITIVE or NEGATIVE PROphet[®] score, which is a clinically validated metric reflecting your likelihood of clinical benefit when treated with PD-1/PD-L1 inhibitors as a single agent or in combination with chemotherapy.

The PROphet[®] score ranges between 0 (lowest clinical benefit probability) to 10 (highest clinical benefit probability).

Based on your score, a PROphet[®] result of POSITIVE or NEGATIVE is assigned to the test, and treatment considerations based on the PROphet[®] score and your PD-L1 result are provided.

* Clinical benefit is determined by Progression Free Survival (PFS) greater than 12 months.



5. What if my report shows that I have a NEGATIVE PROphet[®] result? Does this mean I won't respond to any treatment?

No. This will provide your physician with valuable insights into your first-line treatment plan, giving options that you are likely to respond to based on your personalized proteomic analysis.

6. What if my report shows that I have a POSITIVE PROphet[®] result? Does this mean I will respond to treatment?

This means that you have a high likelihood of achieving clinical benefit on an approved PD-1/PD-L1 inhibitor immunotherapy regimen.

7. When will my results be ready?

Once your blood is drawn and sent to our lab, we will process the sample and prepare your report. Results will be available within 8 days from sample receipt. Your physician will receive a copy of the report once complete and be in touch with you to review the results and discuss next steps.



Who can I contact if I have any questions or need more information?

📞 Contact our client services team at 1-855-950-2112

✉️ Email us at contact@oncohost.com

🌐 Find additional information on our website at www.oncohost.com

OncoHost is empowering oncology care with precision diagnostics. Our mission is to translate the predictive power of proteomics into improved, truly personalized care that makes a real difference in the lives of cancer patients worldwide.

Thank you for including us in your journey.